
OUR APPROACH
We are a diverse and passionate team with a united vision of making a true and lasting difference to the lives of anaphylaxis sufferers worldwide. We believe in our product and the positive impact it will have in revolutionising the way anaphylaxis is treated.
THE PROBLEM

Est. 156 million people ae affected by anaphylaxis

60% don’t carry their EpiPen

30-45% who do carry refuse to administer

Current solutions are unstable in harsh environments
“Anaphylaxis is a severe, potentially life-threatening allergic reaction that requires immediate treatment with adrenaline (epinephrine). Current treatments like traditional adrenaline injectors, despite their effectiveness, face significant practical issues that limit their use. Patients report issues such as bulkiness of the device, short shelf life, temperature susceptibility, and the hesitation to use it due to needle phobia. Consequently, many patients are either reluctant to carry or use their adrenaline injector, leading to increased risk during an anaphylaxis."
Allergy Specialist
OUR SOLUTION



“Our product provides a holistic solution, solving all identified problems with current adrenaline delivery systems. Our solution will minimise delayed or absent administration of adrenaline and improve patients' quality of life.”
Liam Mahony 

Adracard CEO & Anaphylaxis sufferer
Accessible
Easy to use
Economical
KEY UPDATES
OUR TEAM
EXECUTIVE
Our team is committed to bringing innovative solutions to market.



Dr. Liam Mahony
Founder & CEO
Lachlan Timms
Founder & CTO
Paul Carboon
Executive Director
ADVISORY BOARD





Dr. Katie Allen
Renowned allergy researcher and clinician
Dr. Narinder Singh
ENT
Dr. Paul Wynne
Organic chemist & drug project manager
Eddie Walker
IP attorney for FB Rice
Emma Cleary
Director

Device Technologies
